Research Topics
| O StalSummaryCountry: Sweden Publications
| Collaborators
|
Detail Information
Publications
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patientsPia Wegman
Department of Biomedicine and Surgery, Division of Cellbiology, Faculty of Health Sciences, Linkoping, Sweden
Breast Cancer Res 7:R284-90. 2005..We therefore investigated the genotypes of CYP2D6 and SULT1A1 in 226 breast cancer patients participating in a trial of adjuvant tamoxifen treatment in order to validate the benefit from the therapy...- Akt kinases in breast cancer and the results of adjuvant therapyOlle Stal
Department of Biomedicine and Surgery, Division of Oncology, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
Breast Cancer Res 5:R37-44. 2003..It mediates cell survival by acting as a transducer of signals from growth factor receptors that activate phosphatidylinositol 3-kinase... - S-phase fraction assessed by a variant of the rectangular model adapted to the flow-cytometric DNA histogram profileO Stal
Department of Oncology, Faculty of Health Sciences, Linkoping University, Sweden
Cytometry 33:487-91. 1998..The new variant is thought to circumvent some of the problems concerning subjectivity and disturbances caused by aggregate peaks... - ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancerO Stal
Department of Biomedicine and Surgery, Linkoping University, Sweden
Ann Oncol 11:1545-50. 2000..We aimed to study the importance of erbB2 status in early stage postmenopausal breast cancer for patients who participated in a trial of five vs. two years of adjuvant tamoxifen... - Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer GroupM Fernö
Department of Oncology, University Hospital, Lund, Sweden
Breast Cancer Res Treat 59:69-76. 2000.... - Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patientsG Pérez-Tenorio
Department of Biomedicine and Surgery, Division of Oncology, Clinical Research Center, Faculty of Health Sciences, Linkoping University, SE 581 85 Linkoping, Sweden
Br J Cancer 86:540-5. 2002..004). The results suggest that activation of Akt may have prognostic relevance in breast cancer... - Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancerJ Bostner
Department of Biomedicine and Surgery, Division of Oncology, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
Oncogene 26:6997-7005. 2007..In addition, we show that high pak1 protein levels may predict tamoxifen insensitivity... - Different calculation methods for flow cytometric S-phase fraction: prognostic implications in breast cancer? The Swedish Society of Cancer Study GroupB Baldetorp
Department of Oncology, University Hospital, Lund, Sweden
Cytometry 33:385-93. 1998..The nonparametric Rmin, with an automatic setting of the region used for SPF calculation, may be an alternative, but suffers from the disadvantage of not being commercially available yet... - Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancerG Adell
Division of Oncology, Department of Biomedicine and Surgery, University Hospital, Linkoping, Sweden
Int J Radiat Oncol Biol Phys 50:659-63. 2001..Rectal cancer is a common malignancy, with significant local recurrence and death rates. Preoperative radiotherapy and refined surgical technique can improve local control rates and disease-free survival... - Proliferative responses to altered 17beta-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptorsA Jansson
Department of Biomedicine and Surgery, Division of Oncology, Linkoping University, S 581 85 Linkoping, Sweden
Endocr Relat Cancer 13:875-84. 2006..Expression of 17HSD type 1 seems to be dominant to 17HSD type 2. Therefore, it may be important to investigate a ratio between 17HSD type 1 and 17HSD type 2... - Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trialP L Jerevall
Department of Clinical and Experimental Medicine, Division of Oncology, Faculty of Health Sciences, Linkoping University, Linkoping, SE58185, Sweden
Br J Cancer 104:1762-9. 2011..The study objective was to demonstrate the prognostic utility of the combined index in early-stage breast cancer... - C-erbB-2 overexpression and survival in early onset breast cancerM Agrup
Department of Biomedicine and Surgery, Faculty of Health Sciences, Linkoping University, Sweden
Breast Cancer Res Treat 63:23-9. 2000..Moreover, the adverse prognosis associated with c-erbB-2 overexpression in node-positive patients was observed whether or not the patients had received adjuvant chemotherapy... - 17beta-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancerC Gunnarsson
Department of Biomedicine and Surgery, Division of Oncology, Faculty of Health Sciences, Linkoping, Sweden
Br J Cancer 92:547-52. 2005..0051). The expression of 17HSD types 1 and 2 in breast cancer differs from the expression of these enzymes in normal mammary gland, and this study indicates that the expression has prognostic significance in breast cancer... - Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: Novel treatment predictive factors identifiedH Green
Clinical Pharmacology, Department of Medical and Health Sciences, Linkoping University, Linkoping, Sweden, and Science for Life Laboratory, Division of Gene Technology, Royal Institute of Technology, Solna, Sweden
Cancer Lett 313:145-53. 2011..PLD is a safe and effective treatment for elderly breast cancer patients. Also potential predictive markers were identified...